Risk of death in heart disease is associated with elevated urinary globotriaosylceramide

Simple item page
dc.contributor.authorSchiffmann, R.
dc.contributor.authorForni, S.
dc.contributor.authorSwift, C.
dc.contributor.authorBrignol, N.
dc.contributor.authorWu, X.
dc.contributor.authorLockhart, D.
dc.contributor.authorBlankenship, D.
dc.contributor.authorWang, X.
dc.contributor.authorGrayburn, P.
dc.contributor.authorTaylor, M.
dc.contributor.authorLowes, B.
dc.contributor.authorFuller, M.
dc.contributor.authorBenjamin, E.
dc.contributor.authorSweetman, L.
dc.date.issued2014
dc.description.abstractBACKGROUND: Elevated urinary globotriaosylceramide (Gb3) has been considered a hallmark of Fabry disease, an X-linked lysosomal disorder that is a risk factor for most types of heart disease. METHODS AND RESULTS: We screened 1421 consecutive patients with common forms of heart disease for Fabry disease by measuring urinary Gb3 in whole urine using tandem mass spectrometry, α-galactosidase A activity in dried blood spots, and we looked for GLA mutations by parallel sequencing of the whole gene (exons and introns) in pooled genomic DNA samples followed by Sanger sequencing verification. GLA variants were found in 13 patients. In the 1408 patients without GLA mutations, urinary Gb3 levels were significantly higher in heart disease patients compared to 116 apparently healthy controls (median difference=10.0 ng/mL and P<0.001). Urinary lipid profiling showed that levels of 5 other lipids significantly distinguished between urine of patients with Fabry disease (n=7) and heart disease patients with elevated urinary Gb3 (n=6). Sphingomyelin and Gb3 levels were abnormal in the left ventricular wall of patients with ischemic heart failure. Elevated levels of urinary Gb3 were independently associated with increased risk of death in the average follow-up of 17 months (hazard ratio=1.59 for increase in Gb3 of 200, 95% CI=1.36 and 1.87, and P<0.0001). CONCLUSIONS: In heart disease patients who do not have Fabry disease or GLA gene mutations, a higher level of urinary Gb3 is positively associated with near-term mortality. The elevation of urinary Gb3 and that of other lipids suggests that heart disease is associated with multiorgan lipid abnormalities. CLINICAL TRIAL REGISTRATION URL: clinicaltrials.gov. Unique Identifier: NCT01019629.
dc.description.statementofresponsibilityRaphael Schiffmann, Sabrina Forni, Caren Swift, Nastry Brignol, Xiaoyang Wu, David J. Lockhart, Derek Blankenship, Xuan Wang, Paul A. Grayburn, Matthew R. G. Taylor, Brian D. Lowes, Maria Fuller, Elfrida R. Benjamin, Lawrence Sweetman
dc.identifier.citationJournal of the American Heart Association, 2014; 3(1):e000394-1-e000394-29
dc.identifier.doi10.1161/JAHA.113.000394
dc.identifier.issn2047-9980
dc.identifier.issn2047-9980
dc.identifier.orcidFuller, M. [0000-0001-9092-8942]
dc.identifier.urihttp://hdl.handle.net/2440/94412
dc.language.isoen
dc.publisherAmerican Heart Association
dc.rights© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
dc.source.urihttps://doi.org/10.1161/jaha.113.000394
dc.subjectglobotriaosylceramide; heart disease; risk factor; sphingolipids
dc.titleRisk of death in heart disease is associated with elevated urinary globotriaosylceramide
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_94412.pdf
Size:
1.83 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Pathology publications